JP2003525031A - 交雑種核移植によって産生された胚細胞または幹様細胞系及びドナー細胞の遺伝子改変または組織培養条件によって胚発達を増強する方法 - Google Patents

交雑種核移植によって産生された胚細胞または幹様細胞系及びドナー細胞の遺伝子改変または組織培養条件によって胚発達を増強する方法

Info

Publication number
JP2003525031A
JP2003525031A JP2001523749A JP2001523749A JP2003525031A JP 2003525031 A JP2003525031 A JP 2003525031A JP 2001523749 A JP2001523749 A JP 2001523749A JP 2001523749 A JP2001523749 A JP 2001523749A JP 2003525031 A JP2003525031 A JP 2003525031A
Authority
JP
Japan
Prior art keywords
cells
cell
human
stem
embryonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001523749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003525031A5 (cg-RX-API-DMAC7.html
Inventor
ロブル、ジェイムズ
シベリ、ホセ
スタイス、スティーブン、エル
Original Assignee
ユニバシティ オブ マサチューセッツ、ア パブリック インスチチユーション オブ ハイアー エデュケイション オブ ザ コモンウエルス オブ マサチューセッツ、アズ リプリゼンテッド バイ イッツ アマースト キャンパス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバシティ オブ マサチューセッツ、ア パブリック インスチチユーション オブ ハイアー エデュケイション オブ ザ コモンウエルス オブ マサチューセッツ、アズ リプリゼンテッド バイ イッツ アマースト キャンパス filed Critical ユニバシティ オブ マサチューセッツ、ア パブリック インスチチユーション オブ ハイアー エデュケイション オブ ザ コモンウエルス オブ マサチューセッツ、アズ リプリゼンテッド バイ イッツ アマースト キャンパス
Publication of JP2003525031A publication Critical patent/JP2003525031A/ja
Publication of JP2003525031A5 publication Critical patent/JP2003525031A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
JP2001523749A 1999-09-14 2000-09-14 交雑種核移植によって産生された胚細胞または幹様細胞系及びドナー細胞の遺伝子改変または組織培養条件によって胚発達を増強する方法 Pending JP2003525031A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39536899A 1999-09-14 1999-09-14
US09/395,368 1999-09-14
PCT/US2000/025090 WO2001019977A1 (en) 1999-09-14 2000-09-14 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions

Publications (2)

Publication Number Publication Date
JP2003525031A true JP2003525031A (ja) 2003-08-26
JP2003525031A5 JP2003525031A5 (cg-RX-API-DMAC7.html) 2007-11-15

Family

ID=23562752

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001523749A Pending JP2003525031A (ja) 1999-09-14 2000-09-14 交雑種核移植によって産生された胚細胞または幹様細胞系及びドナー細胞の遺伝子改変または組織培養条件によって胚発達を増強する方法

Country Status (10)

Country Link
EP (1) EP1214404A4 (cg-RX-API-DMAC7.html)
JP (1) JP2003525031A (cg-RX-API-DMAC7.html)
CN (1) CN1379814A (cg-RX-API-DMAC7.html)
AU (1) AU7701900A (cg-RX-API-DMAC7.html)
BR (1) BR0013999A (cg-RX-API-DMAC7.html)
CA (1) CA2384413A1 (cg-RX-API-DMAC7.html)
IL (2) IL148547A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02002744A (cg-RX-API-DMAC7.html)
NZ (1) NZ517609A (cg-RX-API-DMAC7.html)
WO (1) WO2001019977A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696404B2 (en) 1996-08-19 2010-04-13 Advanced Cell Technology, Inc. Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions
IL148418A0 (en) * 1999-09-07 2002-09-12 Advanced Cell Tech Inc Method for generating immune-compatible cells and tissues using nuclear transfer techniques
JP2003512052A (ja) * 1999-10-15 2003-04-02 アドバンスド セル テクノロジー、インコーポレイテッド 分化前駆細胞及び系統欠失胚性幹細胞の産生方法
JP2004500066A (ja) * 1999-12-20 2004-01-08 ユニバシティ オブ マサチューセッツ、ア パブリック インスチチユーション オブ ハイアー エデュケイション オブ ザ コモンウエルス オブ マサチューセッツ、アズ リプリゼンテッド バイ イッツ ア 異種間核移植により生成する胚あるいは幹様細胞
US7221981B2 (en) 2002-03-28 2007-05-22 Northstar Neuroscience, Inc. Electrode geometries for efficient neural stimulation
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045100A1 (en) * 1998-03-02 1999-09-10 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Embryonic or stem-like cell lines produced by cross-species nuclear transplantation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
BR9711204A (pt) * 1996-08-19 1999-08-17 Univ Massachusetts Linhagens de c-lulas embriÄnicas ou similares s indiferenciadas produzidas por transplante nuclear de esp-cies hibridas
WO1999005266A2 (en) * 1997-07-26 1999-02-04 Wisconsin Alumni Research Foundation Trans-species nuclear transfer
JP2004500066A (ja) * 1999-12-20 2004-01-08 ユニバシティ オブ マサチューセッツ、ア パブリック インスチチユーション オブ ハイアー エデュケイション オブ ザ コモンウエルス オブ マサチューセッツ、アズ リプリゼンテッド バイ イッツ ア 異種間核移植により生成する胚あるいは幹様細胞

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045100A1 (en) * 1998-03-02 1999-09-10 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Embryonic or stem-like cell lines produced by cross-species nuclear transplantation

Also Published As

Publication number Publication date
MXPA02002744A (es) 2003-07-21
NZ517609A (en) 2004-02-27
EP1214404A4 (en) 2003-09-03
CN1379814A (zh) 2002-11-13
IL148547A (en) 2009-09-01
WO2001019977A9 (en) 2002-09-26
EP1214404A1 (en) 2002-06-19
CA2384413A1 (en) 2001-03-22
WO2001019977A1 (en) 2001-03-22
AU7701900A (en) 2001-04-17
BR0013999A (pt) 2002-05-21
IL148547A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
AU740709B2 (en) Embryonic or stem-like cell lines produced by cross species nuclear transplanta tion
AU759322B2 (en) Embryonic or stem-like cell lines produced by cross-species nuclear transplantation
JP2001509362A (ja) 分化細胞からのドナー核を使用するブタのクローニング
JP2001512964A (ja) 分化した胎仔および成体ドナー細胞による核移植
US20010012513A1 (en) Embryonic or stem-like cell lines produced by cross species nuclear transplantation
CA2317494A1 (en) Cloning using donor nuclei from differentiated fetal and adult cells
JP2002537803A (ja) 異種間核移植により産生される胚性細胞株あるいは幹様細胞株
US7696404B2 (en) Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions
AU784731B2 (en) Embryonic or stem-like cells produced by cross species nuclear transplantation
WO2001084920A1 (en) The production of agricultural animals from embryonic stem (es) cells
CA2381124A1 (en) Cloning pigs using donor cells or nuclei from differentiated cells and production of pluripotent porcine
AU2008229989A1 (en) Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions
WO2001019977A1 (en) Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions
US20020194637A1 (en) Embryonic or stem-like cell lines produced by cross species nuclear transplantation
AU2005225103A1 (en) Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions
AU2006201208A1 (en) Embryonic or stem-like cells produced by cross species nuclear transpantation
MXPA00008602A (en) Embryonic or stem-like cell lines produced by cross-species nuclear transplantation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101126